Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07213674 · ClinicalTrials.gov registry record · Phase 3

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

A Phase 3 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Amgen.

Recruiting
Registry status
Phase 3
Development phase
750
Enrollment target
20
Study locations

NCT07213674 is a Phase 3 study of Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by Amgen. The registered enrollment target is 750 participants, above the 187-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (301% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07213674, a Phase 3 study of Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by Amgen.

RECRUITING
Registry status
Phase 3
Development phase
750 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer

Interventions

  • DRUG Docetaxel
  • DRUG Xaluritamig
  • DRUG Cabazitaxel
  • DRUG Abiraterone acetate

Study Locations (20)

Other

  • Ordensklinikum Linz Elisabethinen - Linz
  • Universitaetsklinikum Sankt Poelten - Sankt Pölten
  • Krankenhaus der Barmherzigen Brueder Wien - Vienna
  • Universitaetsklinikum Allgemeines Krankenhaus Wien - Vienna

California

  • City of Hope National Medical Center - Duarte
  • City of Hope Orange County Lennar Foundation Cancer Center - Duarte
  • Providence Saint Jude Medical Center - Fullerton

Queensland

  • Icon Cancer Care Wesley - Herston
  • Tasman Oncology Research - Southport

Victoria

  • Monash Medical Centre - Clayton
  • Austin Health, Austin Hospital - East Melbourne

Colorado

  • Rocky Mountain Cancer Centers - Denver

Illinois

  • University of Illinois Chicago - Chicago

Kentucky

  • Norton Cancer Institute - Louisville

Ohio

  • Oncology Hematology Care Incorporated - Cincinnati

Trial Details

FieldValue
Enrollment Target 750 participants
Start Date 2025-11-28
Est. Completion 2032-08-30
Phase Phase 3

Sponsor

Amgen

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07213674

The ClinicalTrials.gov registry entry for NCT07213674 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 750 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 187-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (301% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Docetaxel is the first listed.

NCT07213674 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, California, Queensland.

Frequently Asked Questions

What is clinical trial NCT07213674 about?

NCT07213674 is a clinical study titled "A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer". The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).

What is the current status of trial NCT07213674?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 750 participants. The study started on 2025-11-28. Estimated completion is 2032-08-30.

What conditions does trial NCT07213674 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT07213674?

The interventions under investigation include: Docetaxel (DRUG), Xaluritamig (DRUG), Cabazitaxel (DRUG), Abiraterone acetate (DRUG).

Who is sponsoring clinical trial NCT07213674?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07213674 being conducted?

This trial has 20 study locations across California, Colorado, Illinois, Kentucky, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Castration-Resistant Prostate Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.